^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Bavencio (avelumab)

    i
    Other names: MSB0010718C, PF-06834635, MSB-0010718C, COMPOUND 2055269, MSB 0010718C, PF06834635, PF 06834635
    Company:
    EMD Serono
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    13h
    TG4001.12: Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers (clinicaltrials.gov)
    P1/2, N=143, Active, not recruiting, Transgene | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Bavencio (avelumab) • tipapkinogene sovacivec (TG4001)
    18h
    Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) (clinicaltrials.gov)
    P1/2, N=2, Terminated, Ariceum Therapeutics GmbH | N=50 --> 2 | Trial completion date: Dec 2026 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Dec 2025; Study terminated due to strategic business decisions.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • Zynyz (retifanlimab-dlwr) • SOMther (lutetium-177 DOTA satoreotide)
    19h
    A091802: Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: Dec 2026 --> Feb 2025
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    Erbitux (cetuximab) • Bavencio (avelumab)
    4d
    Checkpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity. (PubMed, Adv Ther)
    Immunotherapy has expanded therapeutic GTN, transforming refractory disease as a result of its immune responsiveness. Checkpoint inhibition not only achieves high remission rates but also offers fertility preservation and long-term survivorship. The future challenge lies in optimizing combination strategies, refining biomarkers, and ensuring equitable global access to these emerging treatments.
    Review • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    KDR (Kinase insert domain receptor)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Keytruda (pembrolizumab) • Bavencio (avelumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    6d
    A single-arm, open-label, single-center, exploratory phase II clinical study of etoposide capsules combined with bevacizumab and avelumab in the treatment of platinum-resistant or platinum-refractory ovarian cancer (ChiCTR2500111824)
    P2, N=33, Not yet recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New P2 trial
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Avastin (bevacizumab) • Bavencio (avelumab) • etoposide oral
    14d
    INSIGHT: Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors (clinicaltrials.gov)
    P1, N=110, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Bavencio (avelumab) • ImmuFact (eftilagimod alpha)
    15d
    Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=9, Completed, Massachusetts General Hospital | Recruiting --> Completed | N=30 --> 9 | Trial completion date: Dec 2026 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date
    |
    Keytruda (pembrolizumab) • Bavencio (avelumab)
    15d
    Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study (clinicaltrials.gov)
    P3, N=654, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    IFNA1 (Interferon Alpha 1)
    |
    Bavencio (avelumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    19d
    Treatment Sequencing in Advanced Urothelial Cancer. (PubMed, Drugs)
    Accordingly, gemcitabine-cisplatin with nivolumab and platinum-based chemotherapy followed by maintenance avelumab remain validated evidence-based alternatives, particularly for cisplatin-eligible patients or in regions where enfortumab vedotin plus pembrolizumab is not readily accessible...Enfortumab vedotin monotherapy retains activity post-platinum and immune checkpoint inhibition, erdafitinib provides a targeted benefit in fibroblast growth factor receptor 3-altered tumors, and trastuzumab deruxtecan has emerged as a later-line option for HER2-positive disease. In parallel, circulating tumor DNA is an emerging biomarker with potential to individualize sequencing strategies, although its clinical application remains investigational. This review synthesizes current evidence and highlights practical considerations, emphasizing the need to balance therapeutic innovation with cost effectiveness, equitable access, and global applicability, while identifying critical research priorities in the post-enfortumab vedotin plus pembrolizumab era.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3)
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • Bavencio (avelumab) • Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)
    20d
    NF1/2 mutations predict favorable benefit from immune checkpoint inhibitor-based therapies over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma. (PubMed, Clin Exp Med)
    This tendency was not changed by everolimus (HR = 2.66), but was abrogated slightly by sunitinib (HR = 1.59) and considerably by ICI-based therapies, including nivolumab monotherapy (HR = 1.12), atezolizumab plus bevacizumab (HR = 1.10), and avelumab plus axitinib (HR = 0.69). Overall, our findings suggest that NF1/2 mutations can serve as predictive biomarkers for favorable benefits from ICI-based treatments over VEGFR/mTOR inhibitors in advanced ccRCCs.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    NF1 (Neurofibromin 1)
    |
    EGFR mutation
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • sunitinib • everolimus • Bavencio (avelumab) • axitinib
    20d
    Trial of INI-4001 in Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=50, Recruiting, Inimmune Corporation | Not yet recruiting --> Recruiting | Trial completion date: Apr 2026 --> Mar 2027 | Trial primary completion date: Aug 2024 --> Oct 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • Libtayo (cemiplimab-rwlc)
    21d
    Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies (clinicaltrials.gov)
    P1/2, N=103, Suspended, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jul 2027 | Trial primary completion date: Dec 2025 --> Jul 2027
    Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    Bavencio (avelumab) • peposertib (M3814)